Inactive Instrument

Press Releases Bayer Aktiengesellschaft Other OTC

Equities

BAYRY

US0727303028

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bayer : Address by Bill Anderson	Apr. 26	PU
Bayer : Address by Bill Anderson	Apr. 22	PU
Bayer : Explanations to the Supervisory Board Report - Prof. Dr. Norbert Winkeljohann	Apr. 22	PU
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Apr. 17	EQ
Bayer - AskBio Names Mansuo Shannon Chief Scientific Officer	Apr. 10	AQ
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting	Apr. 04	AQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Apr. 03	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Mar. 27	EQ
Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Mar. 22	EQ
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth	Mar. 21	AQ
Bayer - Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant	Mar. 20	AQ
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing - Evogene	Mar. 20	AQ
Bayer : Information in accordance with Section 125 of the German Stock Corporation Act (AktG) in conjunction with Article 4 and Annex Table 3 of the Commission Implementing Regulation (EU) 2018/1212	Mar. 11	PU
Bayer : Letter from Norbert Winkeljohann, Chairman of the Supervisory Board, to our shareholders	Mar. 10	PU
Bayer : Sample Registration Form	Mar. 07	PU
Bayer : Control and Profit and Loss Transfer Agreement between Bayer Aktiengesellschaft and Bayer CropScience Aktiengesellschaft	Mar. 07	PU
Bayer AG - BlueRock Therapeutics phase I clinical trial for Parkinson's disease continues to show positive trends at 18 months	Mar. 07	AQ
Bayer : Curricula vitae of Jeffrey Ubben	Mar. 06	PU
Bayer : Annual Financial Statements of Bayer CropScience AG 2022	Mar. 06	PU
Bayer : Annual Financial Statements of Bayer CropScience AG 2023	Mar. 06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BAYER : Another year of patience needed

May 01, 2024 at 11:38 am EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST